Dogwood Therapeutics, Inc.
DWTXNasdaq
$1.38
↑ +0.7%Jul 17 close · end-of-day
Price
1Y↓ -69.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$46.3M
Enterprise Value
$33.1M
P/E
1.2
P/S
—
P/B
0.6
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$28.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.1%
ROIC
-33.5%
Debt / Equity
—
Net Cash
$13.2M
Return 1Y
-71.0%
Company profile
Dogwood Therapeutics Inc. focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
- CEO
- Greg Duncan
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 5
- Headquarters
- Georgia
- Website
- dwtx.com
Earnings
DWTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.15↓ -98.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$10.0M | -$15.6M | -$12.3M | -$5.4M | -$12.2M | -$28.0M |
| Net income | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M |
| Diluted EPS | -$2.10 | -$1.92 | -$1.11 | -$7.05 | -$12.52 | -$7.13 |
| Operating cash flow | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.1M | -$2.3M | -$7.5M | -$4.4M | -$3.9M | -$15.8M | -$3.8M | -$5.1M |
| Net income | -$1.0M | -$2.3M | -$7.7M | -$10.9M | -$3.8M | -$15.7M | -$3.8M | -$5.0M |
| Diluted EPS | -$1.15 | -$2.05 | -$7.64 | -$8.45 | -$1.99 | -$8.20 | $11.51 | -$0.15 |
| Operating cash flow | -$811,746.00 | -$910,137.00 | -$6.1M | -$4.7M | -$4.0M | -$3.3M | -$3.6M | -$4.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-11-21 | Sealbond Ltd | C | 21,610,950 | — | — | filing |
| 2025-11-21 | Sealbond Ltd | C | 2,842,638 | — | — | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.